BMO Capital downgraded Q32 Bio (QTTB) to Market Perform from Outperform with a price target of $3, down from $22. The company announced an internal restructuring, discontinuing development of its ...
Q32 Bio (NASDAQ:QTTB – Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th.Analysts expect Q32 Bio to post earnings of ($1.25) per share ...
Hosted on MSN2mon
Q32 Bio (QTTB) Upgraded to Buy: What Does It Mean for the Stock?Earnings Estimate Revisions for Q32 Bio This gene editing company is expected to earn -$5.50 per share for the fiscal year ending December 2024, which represents a year-over-year change of 83.2%.
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in ...
Piper Sandler downgraded Q32 Bio (QTTB) to Neutral from Overweight with a price target of $4, down from $20. The firm is surprised by the company’s decision to discontinue complement inhibitor ...
Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy. Trial expansion planned.
Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today ...
QTTB stock opened at $2.88 on Tuesday. Q32 Bio has a 12-month low of $2.60 and a 12-month high of $53.79. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio ...
Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback